Rigel enters agreement with Bristol-Myers

Rigel Pharmaceuticals Inc. (Nasdaq: RIGL) entered a research and development collaboration agreement with Bristol-Myers Squibb Co. (NYSE: BMY) for the use of TGF beta receptor kinase inhibitors in cancer immunotherapies. Shares of Rigel soared 99 cents to $3.54 while Bristol-Myers stock gained 62 cents to $61.14.